Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer.
10.3803/EnM.2011.26.4.345
- Author:
Jae Hee AHN
1
;
Sun Young KIM
;
Ye Ji KIM
;
Suk Young LEE
;
Jae Hyoung LEE
;
Seung Hun KANG
;
Ho Cheol HONG
;
Sae Jeong YANG
;
Hye Jin YOO
;
Ji A SEO
;
Sin Gon KIM
;
Nan Hee KIM
;
Kyung Mook CHOI
;
Sei Hyun BAIK
;
Dong Seop CHOI
;
Hae Yoon CHOI
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Antipsychotic agents;
Differentiated thyroid cancer;
Hyperprolactinemia
- MeSH:
Antipsychotic Agents;
Breast;
Female;
Follow-Up Studies;
Humans;
Hyperprolactinemia;
Iodine;
Middle Aged;
Neoplasm Metastasis;
Prolactin;
Thyroid Gland;
Thyroid Neoplasms;
Whole Body Imaging
- From:Endocrinology and Metabolism
2011;26(4):345-347
- CountryRepublic of Korea
- Language:English
-
Abstract:
Scanning with whole-body 131I scintigraphy after surgery has been a valuable diagnostic modality in the surveillance of patients with differentiated thyroid cancer. Radioiodine uptake is rarely observed in non-lactating breast tissue, which mimics thyroid cancer metastasis. We now report a case of a 45-year-old female thyroid cancer patient who underwent radioiodine therapy, and in whom breast uptake of radioiodine was observed on a post-therapy whole body scan. Her serum prolactin level was elevated to 328 ng/mL at the time of the radioiodine uptake, and the hyperprolactinemia was induced by her antipsychotic medications. Six months after she discontinued that medication, her serum prolactin level was normalized to 12.6 ng/mL and breast uptake of iodine was no longer present in a follow-up whole body scan.
